A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 [preladenant] in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms [extrapyramidal disorders] Among Subjects With Schizophrenia and Schizoaffective Disorders

Trial Profile

A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 [preladenant] in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms [extrapyramidal disorders] Among Subjects With Schizophrenia and Schizoaffective Disorders

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Preladenant (Primary)
  • Indications Antipsychotic-induced movement disorders
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 20 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top